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• Differentiated thyroid cancer (DTC) accounts for 3.8% of all cancers in the U.S., 
with roughly 10% of cases progressing to distant metastatic DTC, which is 
associated with a poor five year survival outcome despite surgery and radioactive 
iodine (1). 
• Recently, novel immunotherapies have attracted attention as a potential 
therapeutic resource in cases of advanced DTC, however, the response to 
therapy has been variable and unpredictable (2).
• Advanced DTC has been associated with an immune suppressive circulating 
phenotype (3) but the intra-tumoral immune 
infiltrate remains to be elucidated. 
Purpose
The overall purpose of the project is to identify immune markers for DTC in order to 
better prognosticate the disease. In doing so, this study aims to identify and compare 
tumor-infiltrating immune markers with those present in the adjacent normal thyroid 
tissue, and collate these immune infiltrates with tumor characteristics.
Methodology
Results





Figure 1. Proposed mechanism of immune escape
• Immune profiling demonstrated significant differences between tumor and adjacent healthy regions, 
particularly in terms of PD-1 and PD-L1 expression and lymphocyte infiltration, indicating that higher 
intratumor infiltration of T regulatory cells, macrophages and PD-1/PD-L1 positive cells may be associated 
with advanced thyroid cancer.  
• Furthermore, the data demonstrates the efficacy of MxIF in gathering valuable information regarding the tumor 
microenvironment, which will have major implications in guiding the selection of patients for immunotherapy. 
• Moving forward, we plan to investigate the immune profile of approximately 60 more samples in order to draw 
more accurate conclusions prior to analyzing differences in infiltrating cells based on clinical characteristics. 
This will then allow us to better identify immune phenotypes associated with thyroid cancer prognosis in order 
to personalize thyroid cancer care.
• Hence, analyzing immune profiles and 
checkpoint expression via multiplex 
immunofluorescence (MxIF) in DTC would 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CD4+ T Cell Populations in 
PDL1 High and Low Patient
CD8+ T Cell Populations in PDL1 
High and Low Patient
Monocyte Populations in PDL1 
High and Low Patient
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Seventeen adult samples from patients 
with DTC were characterized for CD56, 
PD-1, PD-L1, FOXP3, CD3, CD8, CD4, 
CD45, CD68, CD163, INOS, HLA-DR, 
CD33, and CD19 using MxIF (Figure 2).  
Briefly standard pathological 
deparaffination, antigen retrieval and 
staining was performed. Slides were 
scanned, de-coverslipped and the 
fluorophores were quenched using an 
alkaline solution. Slides could then be 
restained to repeat the process. The data 
obtained was analyzed using HALO and a 
positive threshold was assigned based on 
review by a trained researcher. The 
minimum for positive thresholding was 
consistent for each antibody.
Figure 3. A. In comparing antigen expression within the tumor and adjacent normal regions, significant differences in low 
staining intensity PD-1, high staining intensity PD-1, low staining intensity PD-L1, and CD45 expression were evident, as 
indicated by the asterisks (p<0.05).  B-E.  Comparing antigen expression in primary tumor of patients with distant 
metastasis (3), lymph node involvement (3) and low risk tumors (3)
In evaluating the immune profiles, important differences in the immune infiltrates between 
different stages of the cancer were observed. Generally, PD-1 and PD-L1 were highly 
expressed within the tumor, despite variability in lymphocyte infiltration, indicating the 
importance of PD-1 and PD-L1 as potential predictive biomarkers for the aggressiveness of 
thyroid cancer. Tumor from patients with distant metastases demonstrated higher T cell 
infiltration, T regulatory cells, macrophages and PD-L1 positive cells as compared to localized 
tumor.
Figure 4. Illustration of the different T lymphocyte and monocyte subtypes between a high PD-L1 expressing and low 
PD-L1 expressing primary tumor.  Cellular data was derived from colocalization information from aligned images
Figure 5. Cellular Invasion Along the Leading Edge of Tumor.  A.  Example area of PD-1 staining (Orange) of primary tumor leading edge 
(Blue Line).  B.  Example of banding strategy along leading edge.  Tissue was divided into 100 um bands and the percentage of cells 
expressing antigens within each band was measured.  C-F.  Average invasion of individual antigens along the leading edge for all samples.
Figure 2. MxIF Protocol.  Slides are deparifinized and stained 
cyclically across 4 rounds of staining.  Once MxIF is complete, 
an H&E is performed for pathological review and concurrent 
quantification 
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Figure 5: Cellular Invasion Along Leading Edge of TumorFigure 3: Immune Expression in Primary Thyroid Tumor  
Figure 2: Staining  Protocol
A: Immune Cell Expression in Normal Adjacent and Tumor Tissue
B C D E
Figure 4: Colocalized Immune Infiltrates in PD-L1 High and Low 
Patient
C: CD68 Invasion Along the Leading Edge 
E: PD-L1 Invasion Along the Leading Edge 
D: CD45 Invasion Along the Leading Edge 
F: PD-1 Invasion Along the Leading Edge 
A: PD-1 Staining Along Leading Edge B: Banding Invasion Analysis Example
